Measuring the Socioeconomic Impact of Cancer: A Systematic Review and Standardized Assessment of Patient-Reported Outcomes (PRO) Instruments
Phu Duy Pham,
Jasper Ubels,
Rachel Eckford and
Michael Schlander ()
Additional contact information
Phu Duy Pham: German Cancer Research Center (DKFZ)
Jasper Ubels: German Cancer Research Center (DKFZ)
Rachel Eckford: German Cancer Research Center (DKFZ)
Michael Schlander: German Cancer Research Center (DKFZ)
PharmacoEconomics - Open, 2025, vol. 9, issue 4, No 2, 519-539
Abstract:
Abstract Background A number of instruments have been developed to measure the socioeconomic impact (SEI) of cancer. A standardized comparison of the quality and content validity of these instruments is lacking. This study aimed to (1) conduct a standardized assessment of the quality of SEI instruments and (2) assess the content validity of these instruments using the conceptual framework developed by the Organization of European Cancer Institutes (OECI) for SEI analysis. Method We identified articles measuring the SEI of cancer with ad hoc and/or validated instruments from an existing database. These articles were the initial pearls in a systematic review of published articles that applied and validated these instruments using the pearl-growing search strategy in PubMed, Web of Science, and Google Scholar databases. The Evaluating the Measurement of Patient-Reported Outcomes (EMPRO) tool was utilized to provide quantitative assessment and comparison of the quality of identified instruments. To examine content validity, we allocated each instrument’s items against the themes and sub-themes of the established conceptual framework for SEI analysis. Results We identified and investigated 21 validation studies using nine original instruments. The number of articles varied significantly among the identified instruments. The COmprehensive Score for financial Toxicity (COST) instrument was the most frequently used, validated in ten different settings, whereas some newer instruments have not been applied yet. This variation resulted in significant differences in EMPRO overall scores among these instruments. Regarding content validity, we found that not all themes of the OECI framework were covered by the content of the instruments. Conclusion The quality and the application of instruments measuring the SEI of cancer varied significantly. The content of the instruments seems not to cover all related themes of the applied OECI framework in this study. Further studies are warranted to confirm the quality and content validity of the instruments measuring the SEI of cancer.
Date: 2025
References: Add references at CitEc
Citations:
Downloads: (external link)
http://link.springer.com/10.1007/s41669-025-00568-0 Abstract (text/html)
Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
HTML/Text
Persistent link: https://EconPapers.repec.org/RePEc:spr:pharmo:v:9:y:2025:i:4:d:10.1007_s41669-025-00568-0
Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/41669
DOI: 10.1007/s41669-025-00568-0
Access Statistics for this article
PharmacoEconomics - Open is currently edited by Timothy Wrightson and Christopher Carswell
More articles in PharmacoEconomics - Open from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().